Treatment emergent adverse events occurring anytime after AUTO3 infusion in at least 10% patients, regardless of relationship to AUTO3, based on the preferred term (safety set)
| Preferred term . | Total (N = 52) . | |
|---|---|---|
| All grades n (%) . | Grade ≥ n (%) . | |
| Any TEAE | 50 (96.2) | 41 (78.8) |
| Anemia | 27 (51.9) | 21 (40.4) |
| Neutropenia | 20 (38.5) | 19 (36.5) |
| CRS | 19 (36.5) | 1 (1.9) |
| Pyrexia | 17 (32.7) | 1 (1.9) |
| Fatigue | 16 (30.8) | 0 |
| Platelet count decreased | 16 (30.8) | 11 (21.2) |
| Neutrophil count decreased | 15 (28.8) | 15 (28.8) |
| Thrombocytopenia | 12 (23.1) | 11 (21.2) |
| Constipation | 10 (19.2) | 0 |
| Diarrhea | 9 (17.3) | 1 (1.9) |
| Headache | 9 (17.3) | 1 (1.9) |
| Febrile neutropenia | 8 (15.4) | 7 (13.5) |
| Hypotension | 8 (15.4) | 2 (3.8) |
| Edema peripheral | 7 (13.5) | 0 |
| Chills | 6 (11.5) | 0 |
| Dizziness | 6 (11.5) | 0 |
| Hypophosphatemia | 6 (11.5) | 3 (5.8) |
| White blood cell count decreased | 6 (11.5) | 6 (11.5) |
| Preferred term . | Total (N = 52) . | |
|---|---|---|
| All grades n (%) . | Grade ≥ n (%) . | |
| Any TEAE | 50 (96.2) | 41 (78.8) |
| Anemia | 27 (51.9) | 21 (40.4) |
| Neutropenia | 20 (38.5) | 19 (36.5) |
| CRS | 19 (36.5) | 1 (1.9) |
| Pyrexia | 17 (32.7) | 1 (1.9) |
| Fatigue | 16 (30.8) | 0 |
| Platelet count decreased | 16 (30.8) | 11 (21.2) |
| Neutrophil count decreased | 15 (28.8) | 15 (28.8) |
| Thrombocytopenia | 12 (23.1) | 11 (21.2) |
| Constipation | 10 (19.2) | 0 |
| Diarrhea | 9 (17.3) | 1 (1.9) |
| Headache | 9 (17.3) | 1 (1.9) |
| Febrile neutropenia | 8 (15.4) | 7 (13.5) |
| Hypotension | 8 (15.4) | 2 (3.8) |
| Edema peripheral | 7 (13.5) | 0 |
| Chills | 6 (11.5) | 0 |
| Dizziness | 6 (11.5) | 0 |
| Hypophosphatemia | 6 (11.5) | 3 (5.8) |
| White blood cell count decreased | 6 (11.5) | 6 (11.5) |
TEAE, treatment emergent adverse event.